Replies to post #77946 on Ayala Pharmaceuticals Inc (ADXS)

[mm2k]

Unfortunately that pretty much sums it up.

[jckrdu]

IMO Ken does have options on path forward without licensing HOT constructs immediately, which IMO would be giving them away because he's simply not going to be able to command much up-front cash without supporting data.

So, one scenario could be selling 20Mish shares at somewhere between $1 and $1.50 and netting somewhere between $20M - $30M cash (IMO that's what the new CFO is working to get lined-up). If AXAL/Cervical is wound-down, Ken should be able to get annual burn-rate down closer to $35M, so that kind of capital raise would provide almost a year of operating runway... thus letting NEO/HOT data be released, and then do the HOT deals with much better terms.

ADXS would still only have 70M shares outstanding in above scenario, and IMO would be very well-positioned to move higher on NEO/HOT data releases and subsequent bigger money partnerships.

All that said, PSA HOT deal with Merck could come first later this year or early 2019, before any capital raising.

Too many paths forward to speculate on. I'm looking for more clarity at Sept conf call before buying back in.